FDA Clearance Tracker · DEN200080
Paige Prostate
Last checked: Nov 19, 2026Latest source record: Sep 21, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Sep 21, 2021
De Novo granted
Time to decision
264 days
Received Dec 31, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN200080
- Device name
- Paige Prostate
- Applicant
- Paige.Ai
- Applicant location
- New York, NY
- Received
- Dec 31, 2020
- Decided
- Sep 21, 2021
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 864.3750
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN200080
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Paige.Ai
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FullFocus510(k)
K241273 · Decided Jan 9, 2025 · 248 days after receipt
Device type: Digital Pathology Image Viewing And Management Software (QKQ) · Laboratory Medicine & Pathology
- FullFocus510(k)
K201005 · Decided Jul 15, 2020 · 90 days after receipt
Device type: Digital Pathology Image Viewing And Management Software (QKQ) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.